Data from the systematic literature review to determine the relationship between HBsAg (prevalence of HBV infection) and anti-HBc (exposure to HBV infection) in African populations is available on Figshare via the following link: <https://figshare.com/s/4414fce1d474bc8a6198>. Visualisation of HBV sero-epidemiology data for Africa is available on Shinyapps (RStudio) via the following link: <https://hbv-geo.shinyapps.io/oxafricahbv/>. Please note that links to the metadata have been appropriately referenced throughout the manuscript.

Introduction {#sec007}
============

There is an estimated global burden of 290 million cases of hepatitis B virus (HBV) infection \[[@pmed.1003068.ref001]\], the majority of which are undiagnosed and untreated \[[@pmed.1003068.ref002]\]. Prevalence of HBV exposure and chronic hepatitis B (CHB) infection are extremely high in some settings in Africa \[[@pmed.1003068.ref003], [@pmed.1003068.ref004]\]. Robust epidemiology data are lacking, and some populations in Africa have specific vulnerabilities associated with poverty, stigma, and co-endemic human immunodeficiency virus (HIV) infection \[[@pmed.1003068.ref002]\]. Horizontal transmission within households, particularly affecting young children, is a significant acquisition route in some African populations \[[@pmed.1003068.ref005], [@pmed.1003068.ref006]\], but the specific mechanism and timing of transmission remain uncertain in many cases.

Vaccination to protect against infection is a cornerstone of interventions, with enhanced efforts arising as a result of United Nations (UN) Sustainable Development Goals (SDGs) setting out elimination targets for the year 2030 \[[@pmed.1003068.ref007]\]. Vaccination is included in the Expanded Programme for Immunization (EPI) and has been progressively rolled out for infants across Africa since 1995, alongside enhanced interventions for the prevention of mother to child transmission (PMTCT) \[[@pmed.1003068.ref008]\]. However, despite 2 decades of vaccine implementation, CHB remains endemic in many regions, and published mathematical models exploring the impact of existing interventions demonstrate time scales for success that are substantially beyond the 2030 targets \[[@pmed.1003068.ref009], [@pmed.1003068.ref010]\].

Treatment of CHB is typically based on nucleoside/nucleotide analogue (NA) drugs, among which tenofovir disoproxil fumarate (TDF) is the most affordable, accessible, and widely recommended \[[@pmed.1003068.ref008], [@pmed.1003068.ref011]--[@pmed.1003068.ref013]\]. NA agents have a high rate of success in suppressing detectable viraemia, but do not tackle the liver reservoir of virus (in the form of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes \[[@pmed.1003068.ref014]\]), so most individuals are committed to long-term treatment. Individuals with CHB are assessed for treatment based on algorithms that stratify the long-term risk of liver disease based on age and sex, laboratory measurement of liver enzymes and HBV DNA viral load, elastography scores, or other imaging data \[[@pmed.1003068.ref011]--[@pmed.1003068.ref013]\]. Treatment guidelines also recognise and support the use of TDF during pregnancy as part of an approach to reduce vertical transmission \[[@pmed.1003068.ref013]\], and this approach is widely accepted (albeit variably deployed) \[[@pmed.1003068.ref015]\]. However, there is less recognition of the wider potential for NA agents to be deployed as a public health intervention to reduce new incident cases.

Tackling the large, chronic population reservoir of HBV in adults is important, and various strategies are employed to reduce new incident infections in adults. There is an interesting conflict between formal recommendations and public health policies that are deployed in practice. Although evidence suggests that 'catch-up' vaccination campaigns are likely to have limited population benefit \[[@pmed.1003068.ref009]\] and are not endorsed by guidelines \[[@pmed.1003068.ref008]\], the strategy can appear an attractive public health approach for older children and adults in high-prevalence populations \[[@pmed.1003068.ref016]\] and has been undertaken in some settings \[[@pmed.1003068.ref017]\]. Economic analyses have reported that catch-up campaigns in young adults are cost-effective only if combined with screening \[[@pmed.1003068.ref018]\], highlighting the importance of focusing not only on prevention but also on investment in diagnosis and treatment \[[@pmed.1003068.ref019]\]. The latter concept has been embraced for HIV under the banners of Treatment for Prevention (T4P) and, more recently, Universal Test and Treat (T&T) \[[@pmed.1003068.ref020]\], recognising that antiretroviral treatment (ART) confers benefits both to the individual and also to populations by reducing the risk of transmission \[[@pmed.1003068.ref021], [@pmed.1003068.ref022]\].

Building on this experience from HIV, a T&T HBV strategy could offer substantial advantages. The feasibility, acceptability, and public health consequences of this approach have been discussed in reports of HBV treatment deployment in The Gambia \[[@pmed.1003068.ref019], [@pmed.1003068.ref023]\], although previous approaches treat only selected individuals deemed to be at highest risk. Evidence-based consideration of the impact of population-level interventions, including more inclusive approaches for treatment of a greater proportion of all individuals with HBV, are urgently required if we are to accelerate progress towards elimination targets.

We used a systematic literature review to investigate the seroepidemiology of HBV across the African subcontinent in order to highlight regional differences and inform local strategies, with a specific focus on interventions that target adults. Recognising that catch-up campaigns are already being deployed in some locations, we considered the evidence for any benefit of this approach, and in parallel, we assessed the impact of universal T&T using epidemiological data and a mathematical model \[[@pmed.1003068.ref009]\].

Methods {#sec008}
=======

HBV seroepidemiology for Africa {#sec009}
-------------------------------

We undertook a systematic search of PubMed and Web of Science in November 2019, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria to underpin a predefined protocol for data collection ([Fig 1](#pmed.1003068.g001){ref-type="fig"}; [S1 PRISMA Checklist](#pmed.1003068.s001){ref-type="supplementary-material"}). We used the search terms 'HBV antibody,' 'anti-HBc,' 'HB core antibody,' 'HBV exposure,' or 'HBV prevalence' AND 'Africa' or \[Name of specific country\], using the UN geoscheme for Africa to define a list of countries \[[@pmed.1003068.ref024]\]. We assessed the quality of included studies using recommended criteria from the Joanna Briggs Institute \[[@pmed.1003068.ref025], [@pmed.1003068.ref026]\]. Inclusion criteria were as follows:

-   Data gathered after widespread roll-out of infant vaccination in 1995

-   No reported data collection undertaken pre 1995

-   Reported prevalence of both hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc)

-   Cohorts primarily reporting data for adults (age ≥ 16 years)

-   Cohort does not sample a population enriched for HBV infection (specific exclusions are presented in [Fig 1](#pmed.1003068.g001){ref-type="fig"})

![PRISMA flowchart showing selection of studies of HBsAg and anti-HBc prevalence in Africa, published 1995--2019, for inclusion in meta-analysis.\
The analysis included 96 studies; 13 of these studies reported data for 2 discrete cohorts, giving a total of 109 data points included in the final analysis. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](pmed.1003068.g001){#pmed.1003068.g001}

We recorded anti-HBc prevalence (i.e., proportion of population exposed to HBV, irrespective of chronic infection status, also termed 'total exposure') and also calculated the proportion of the population with cleared infection (i.e., anti-HBc prevalence minus HBsAg prevalence, termed 'exposed and cleared'). For studies reporting prevalence data from ≥2 cohorts (e.g., HIV-positive and HIV-negative populations), we recorded these as a single publication but ≥2 discrete data points. We also sought evidence for recommendations underpinning catch-up vaccination of adolescents and adults in Africa cited in PubMed using the search terms 'hepatitis b virus' or 'HBV,' and 'Africa' or \[individual country name\], with 'vaccin\*' and 'catch up' or 'adult.' All studies were evaluated independently by 2 or more authors prior to inclusion in the analysis.

We set out with 2 prespecified aims, (i) to investigate the relationship between the prevalence of CHB infection and HBV exposure for different regions of Africa and (ii) to use an existing model to predict the outcomes of population interventions in a high-prevalence setting.

Statistical analysis of metadata {#sec010}
--------------------------------

In order to derive an estimation of the age group represented by the studies included, we used mean (reported by 48/109 cohorts) and median (reported by 23/109 cohorts). For the remaining 38 cohorts, age was not reported, or the data could not be disaggregated.

The UN geoscheme includes 5 African regions: Central, Eastern, Northern, Southern, and Western \[[@pmed.1003068.ref024]\]. We analysed prevalence data for anti-HBc and HBsAg using Graphpad Prism version 7.0 and R. We used weighted linear regression based on cohort size to derive lines of best fit and 95% confidence intervals and to interpolate data points. We generated maps using R \[[@pmed.1003068.ref027], [@pmed.1003068.ref028]\].

Estimates of pooled median proportions (HBsAg positive, anti-HBc), were obtained through logistic regression with a random intercept assigned to each cohort, performed separately for each African region. The 95% confidence intervals of the proportions were based on profile likelihood of the model's fixed effect intercepts. Comparisons between different regions were obtained by sub-setting the data for each pair of regions and creating 2 models. The first was the logistic regression model with a random intercept assigned to each cohort described earlier, while the second had an added fixed effect of the study region. These 2 models were compared through the likelihood ratio test (LRT). The obtained *p*-values from the LRTs were then adjusted for multiple comparisons using the Holm-Bonferroni method, and the adjusted *p*-values are reported.

Modelling the impact of adult vaccination versus T&T {#sec011}
----------------------------------------------------

In this study, we adapted a previously published HBV dynamic model and Markov chain Monte Carlo (MCMC) approach that we initially developed to fit the seroepidemiology of Kimberley in South Africa to project the impact of interventions in that transmission setting \[[@pmed.1003068.ref009]\]; as our mathematical and computational methods are already published, we have not replicated them in this paper. However, for ease of reference, we have provided a summary overview of model population classes in [Fig 2](#pmed.1003068.g002){ref-type="fig"}, as well as relevant parameters in [S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}.

![Summary diagram of the dynamic model used to fit the seroepidemiology of HBV in Uganda.\
The naïve (grey rounded boxes) and vaccinated (blue rounded boxes) subpopulations are divided into 3 relevant age groups: infant (0--1 years), child (1--6 years), and older (+6 years). This allows us to consider a relationship between the likelihood of developing chronic or acute infection with age (represented by the thickness of the grey and blue arrows). Individuals can acquire infection in any age group. When acutely infected (yellow rounded box), individuals may clear infection and recover (green rounded box). When chronically infected, individuals can be HBeAg positive (purple rounded box) and transit to become HBeAg negative (red rounded box), after which they may recover (green rounded box). Interventions (light blue squared boxes) target different epidemiological states and transitions (orange circles). Vertical transmission can occur from infected mothers to newborns. Protection mediated by infant vaccination is age dependent due to waning and is assumed to lower susceptibility to infection. Parameters are listed in [S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}. Artwork supported by figures created with BioRender.com. anti-HBc, antibody to hepatitis B core antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PMTCT, prevention of mother to child transmission; T&T, Test and Treat.](pmed.1003068.g002){#pmed.1003068.g002}

In this instance, we fitted the model to data from Uganda, a setting of high HBsAg prevalence \[[@pmed.1003068.ref003]\]. Target (model-fitted) seroepidemiology variables were HBsAg prevalence at approximately 10%, anti-HBc prevalence at 42%, and hepatitis B e-antigen (HBeAg) positive relative prevalence at 27% ([S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}). We left 4 model parameters free to be fitted to the Uganda setting (with uninformative priors): vertical transmission rate for HBeAg-positive and HBeAg-negative groups, rate of conversion from HBeAg positive to HBeAg negative, and spontaneous clearance of chronic HBV infection. The MCMC fitted the model closely to the target variables at 10% (95% CI 7.92%--11.7%) for HBsAg prevalence, 42.1% (95% CI 40.2%--44.0%) for anti-HBc prevalence, and 26.9% (95% CI 24.8%--29.0%) for HBeAg-positive relative prevalence. The posteriors of the free parameters also closely matched literature expectations ([S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}).

PMTCT and vaccine-based interventions were modelled as previously described ([Fig 2](#pmed.1003068.g002){ref-type="fig"}) \[[@pmed.1003068.ref009]\]. As the model framework does not allow for risk stratification beyond age groups, we included a simple T&T intervention that reduces the transmission potential of the HBV infected proportionally to control effort (e.g., 20% T&T coverage equated to a 20% reduction in the force of infection). The universal T&T approach thus assumes that HBsAg-positive cases were treated irrespective of any specific risk stratification.

Results {#sec012}
=======

Studies identified through a systematic literature review {#sec013}
---------------------------------------------------------

We collated and curated a total of 96 studies spanning 39 African countries and generating 109 unique data points representing independent cohorts ([Fig 1](#pmed.1003068.g001){ref-type="fig"}; full metadata online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598)). Studies reporting prevalence data from ≥2 cohorts (*n* = 13) are summarised in [S2 Table](#pmed.1003068.s003){ref-type="supplementary-material"}. Across all 109 cohorts, the median number of individuals sampled was 370 (IQR 177--638, range 50--9,486). The median ages for the cohorts represented was 34 years (IQR 29--38 years) based on age data reported for 65% of cohorts.

Quality appraisal of data identified through systematic literature review {#sec014}
-------------------------------------------------------------------------

We undertook a quality assessment of all the studies we identified (full quality appraisal data online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598)). The majority of studies included in the meta-analysis were of good quality, with 85% of studies reporting clear details of the methods used to measure HBsAg and anti-HBc reflecting our stringent criteria for inclusion of these prevalence values. Among 8 of the remaining studies with the poorest quality evaluations, we were unable to evaluate quality of laboratory methods in 7 cases because the journals in question did not support electronic archives dating back far enough to access the full publication, but relevant serological parameters were available from the abstract.

The quality assessment (online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598)) and Forest Plots of the data ([S1 Fig](#pmed.1003068.s006){ref-type="supplementary-material"}) highlighted differences in our confidence in assessment of prevalence of HBsAg and anti-HBc, with sufficient sample sizes reported by 83% and 53% of all included studies for these 2 parameters, respectively. In almost all cases (*n* = 108), HBsAg and anti-HBc were measured in the same cohorts, and the anti-HBc prevalence was frequently considerably higher than the HBsAg, generally requiring larger cohort sizes to ascertain similar levels of confidence. A number of studies reported powering their analysis for assessing HBsAg prevalence, but this was infrequently considered for anti-HBc.

Prevalence of infection (HBsAg) is positively correlated with exposure (anti-HBc) {#sec015}
---------------------------------------------------------------------------------

Cohort spatial distribution and associated serological markers are shown in [Fig 3](#pmed.1003068.g003){ref-type="fig"} and can be visualised using our interactive tool online \[[@pmed.1003068.ref029]\]. Pooling data for all regions, the prevalence of CHB was positively correlated with exposure (*R*^2^ = 0.45, *p* \< 0.001 by weighted linear regression) ([Fig 4A](#pmed.1003068.g004){ref-type="fig"}). Prevalence of CHB differs significantly between regions ([Fig 4B--4F](#pmed.1003068.g004){ref-type="fig"}). Focusing specifically on Uganda, we also found a significant relationship between CHB prevalence and exposure (*p* = 0.006, [Fig 4G](#pmed.1003068.g004){ref-type="fig"}), although considerable CHB prevalence/exposure ratio variation is seen between different Ugandan studies.

![Maps demonstrating the location and HBV seroepidemiology of adult cohorts identified through a systematic literature review.\
First row shows data by individual cohort, depicting (A) HBsAg prevalence, (B) anti-HBc prevalence (exposed plus infected), and (C) HBV susceptible population (100% of population minus anti-HBc prevalence). Each circle is placed to represent the location of the cohort. Second row shows data by country (D--F) and third row by region (G--I). Each area is coloured to reflect high to low prevalence of the attribute in question (scale bar as shown on each panel). Countries shown in grey have no data. The cohort metadata are available online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598), and an interactive version of these maps can be accessed online \[[@pmed.1003068.ref029]\]. Outline maps available as open source from <http://www.maplibrary.org/library/index.htm>. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.](pmed.1003068.g003){#pmed.1003068.g003}

![Relationship between population prevalence of anti-HBc (exposure) and HBsAg (active infection) for different regions of Africa.\
Data are shown for (A) the entire African continent; for (B) Western, (C) Central, (D) Northern, (E) Southern, and (F) Eastern Africa; and for (G) Uganda. These data are derived from a review of the published literature, using UN geoschemes to classify the geographic regions \[[@pmed.1003068.ref024]\]. *R*^2^ and *p*-values by weighted linear regression (solid line), with studies weighted by cohort size. Outer dashed lines show 95% confidence intervals. Weighted linear regression plots and 95% CIs (shaded regions) are shown for the whole of Africa in red, for each region in grey. Linear regression lines of fit in plots B--G have been shown together with the fit for the whole continent for comparison. In each plot, the dots represent only studies associated with that region. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; UN, United Nations.](pmed.1003068.g004){#pmed.1003068.g004}

There are striking differences in seroprevalence by country ([Fig 5A](#pmed.1003068.g005){ref-type="fig"}) and by region ([Fig 5B](#pmed.1003068.g005){ref-type="fig"}). For example, HBsAg prevalence in Northern Africa is lower compared to Western and Southern Africa (*p* \< 0.001 and *p* = 0.007, respectively, [Fig 5B](#pmed.1003068.g005){ref-type="fig"}), but this difference cannot be explained only by lower population exposure (anti-HBc) rates: although exposure is lower in Northern than Western Africa (*p* \< 0.001), there is no difference in exposure between Southern and Northern Africa (*p* = 0.5). Indeed, the predicted CHB prevalence was generally 30% to 40% lower in Northern than Southern Africa for any given exposure ([Fig 4D and 4E](#pmed.1003068.g004){ref-type="fig"}; [S3 Table](#pmed.1003068.s004){ref-type="supplementary-material"}). Central African regions display a different relationship between HBsAg and anti-HBc, compared to other settings whereby high exposure is not associated with a correspondingly high prevalence of CHB infection ([Fig 4C](#pmed.1003068.g004){ref-type="fig"}). This is likely to be a robust representation of the region, as the data are presented by 14 studies published over a 16-year period and represent multiple countries in which a median of 383 individuals were analysed (IQR 201--772 individuals).

![Estimated proportion of the population with chronic HBV infection (HBsAg), total exposure (anti-HBc), and susceptibility to HBV infection, divided by (A) country and (B) region of Africa.\
Countries have been grouped by region according to the UN geoscheme for Africa \[[@pmed.1003068.ref024]\]. The number of studies per country is given in brackets next to the country name. Two studies were counted twice as they contained cohorts from 2 different countries. Per-country estimations were calculated, weighting individual studies according to cohort size. In panel (B), boxplots show the weighted estimations of prevalence with 95% confidence intervals, with significant differences indicated. See methods for definitions of infection, previous exposure, and susceptibility. Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; UN, United Nations.](pmed.1003068.g005){#pmed.1003068.g005}

We did not find any significant differences in prevalence or exposure between HIV-positive cohorts (*n* = 27) and all other cohorts (*n* = 79; both *p* \> 0.05; [S2 Fig](#pmed.1003068.s007){ref-type="supplementary-material"}). In 3 studies that assessed both HIV-positive and HIV-negative cohorts, CHB prevalence was consistently higher among HIV-positive patients (mean 2.23-fold) \[[@pmed.1003068.ref030]--[@pmed.1003068.ref032]\]. Exposure was also higher in HIV-positive cohorts than in HIV-negative cohorts for two-thirds of studies \[[@pmed.1003068.ref031], [@pmed.1003068.ref032]\]. In a third study in South Africa, exposure was similar irrespective of HIV status, suggesting that the increased CHB prevalence in the HIV-positive cohort was the result of reduced clearance rates relative to the HIV-negative cohort \[[@pmed.1003068.ref030]\].

Impact of catch-up vaccination of adolescents and adults in highly endemic settings {#sec016}
-----------------------------------------------------------------------------------

We did not identify any published evidence or specific recommendations for catch-up of adolescents and adults. However, a number of authors suggest catch-up programmes as a way of tackling high HBV prevalence \[[@pmed.1003068.ref003], [@pmed.1003068.ref016], [@pmed.1003068.ref033], [@pmed.1003068.ref034]\] (all the relevant studies and recommendations are summarised in [S4 Table](#pmed.1003068.s005){ref-type="supplementary-material"}).

Based on combining the mean prevalence values from Uganda cohorts to provide a broad overview, 54% of adults across this country have been exposed to HBV (among these, 11% of adults are actively HBV infected, and the remainder have serological evidence of resolved infection). This leaves 46% of the total adult population potentially susceptible (orange bars, [Fig 5A](#pmed.1003068.g005){ref-type="fig"}). Only a small proportion of this susceptible pool of adults would be exposed to HBV infection each year (estimated in another East African study at 3%--4%) \[[@pmed.1003068.ref035]\]. The natural history of infection in otherwise healthy adults suggests that \<5% of exposure events lead to CHB. Thus, the proportion of the total adult population predicted to avoid CHB through catch-up vaccination each year is, roughly, 50% (vulnerable) × 4% (exposed) × 5% (develop chronicity) = 0.1%.

Using our HBV dynamic model (summarised in [Fig 2](#pmed.1003068.g002){ref-type="fig"}, and with details previously published \[[@pmed.1003068.ref009]\]), we investigated the impact of catch-up vaccination among adults within a high-prevalence setting, exemplified by Uganda \[[@pmed.1003068.ref003]\] (based on parameters listed in [S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}). The predicted short-term impact of interventions is shown in [Fig 6A--6E](#pmed.1003068.g006){ref-type="fig"} with longer-term predictions in [Fig 6F](#pmed.1003068.g006){ref-type="fig"}. While projecting that catch-up vaccination of all individuals mediates an estimated 16% reduction over 50 years ([Fig 6A](#pmed.1003068.g006){ref-type="fig"})---and routine catch-up vaccination of the age group \>6 years is predicted to bring about an 11% reduction ([Fig 6B](#pmed.1003068.g006){ref-type="fig"})---it is noteworthy that the impact of this strategy disappears over longer time scales ([Fig 6F](#pmed.1003068.g006){ref-type="fig"}). This decline in impact is due to a limited pool of susceptible adults and the lack of direct impact on the actively infected population. In the long term, this suggests that the strategy offers no sustained overall benefit in progress towards elimination targets, even when deployed at 100% coverage. In contrast, our projections suggest that enhanced coverage of other interventions---including infant immunisation ([Fig 6C](#pmed.1003068.g006){ref-type="fig"}) and PMTCT ([Fig 6D](#pmed.1003068.g006){ref-type="fig"})---could lead to much higher impact, both in the shorter and longer terms.

![Decline in HBsAg prevalence over time in response to population interventions for HBV infection in Uganda.\
Decline in prevalence is shown over time starting at approximately 10% as used for model fitting to the Uganda setting (see main text). Shaded areas show 95% confidence interval for each intervention based on 5,000 stochastic simulations using parameter samples from the posteriors obtained by fitting the model. Comparisons of interventions applied to 100% of the population: (A) catch-up vaccination of all ages as a one-off event at time = 0 (orange); (B) routine immunisation of children as they reach 6 years of age (proxy for school age) (green); (C) routine neonatal immunisation (blue); and (D) PMTCT interventions for all births (combining accelerated neonatal immunisation with HBIg and antiviral therapy in pregnant mothers, red). (E) Comparison of a T&T approach applied to different proportions of the population: 50% of individuals older than 6 years, 80% of individuals older than 6 years, 50% of population, 80% of population, and 100% of population (purple solid line). This demonstrates the impact of reduced proportions of the population exposed to drug therapy, as a result of either not having drug prescribed or noncompliance with prescribed therapy. (F) Interventions shown in A--E applied to 100% of the population were run for an extended time period of 500 years to observe long-term effects. The numbers at time points t = 20 and t = 50 years, incorporating an overall timeframe that includes the 2030 elimination targets, show the mean reduction in HBsAg prevalence achieved for each of the interventions: (A) 11% (95% CI 9%--15%) and 16% (13%--20%); (B) 3% (2%--5%) and 11% (9%--15%); (C) 14% (12%--18%) and 39% (34%--47%); (D) 13% (10%--15%) and 31% (25%--35%); and (E) 33% (30%--37%) and 62% (57%--68%). HBIg, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PMTCT, prevention of mother to child transmission; T&T, Test and Treat.](pmed.1003068.g006){#pmed.1003068.g006}

Impact of T&T in highly endemic settings {#sec017}
----------------------------------------

We investigated the projected impact of T&T, concluding that it has the highest impact of the modelled interventions; at 100% coverage, this leads to 33% reduction in prevalence by 20 years (95% CI 30%--37%) and 62% at 50 years (95% CI 57%--68%) ([Fig 6E](#pmed.1003068.g006){ref-type="fig"}). Recognising the significant barriers to identifying all cases of CHB (which include silent infection, lack of education and awareness, poor access to clinical and laboratory facilities, and stigma \[[@pmed.1003068.ref002], [@pmed.1003068.ref036], [@pmed.1003068.ref037]\]), we also modelled the outcome for T&T strategies that reach \<100% of the population. Diagnosis and treatment for 80% of infected adults or 50% of the whole infected population ([Fig 6E](#pmed.1003068.g006){ref-type="fig"}, dashed lines) still deliver a projected reduction in prevalence over time that is comparable to infant immunisation ([Fig 6F](#pmed.1003068.g006){ref-type="fig"}). Even reducing the target to only 50% of adults ([Fig 6E](#pmed.1003068.g006){ref-type="fig"}) is still substantially more effective than 100% catch-up vaccination ([Fig 6A](#pmed.1003068.g006){ref-type="fig"}).

Discussion {#sec018}
==========

Summary of main findings {#sec019}
------------------------

In this study, we set out to evaluate the relationship between the prevalence of CHB infection and exposure in different settings. We suggest that determinants of CHB prevalence involve numerous factors, including age at exposure ([Fig 7A](#pmed.1003068.g007){ref-type="fig"}), route of infection, host genetics, and viral genotype, and interactions between them remain poorly understood. Using a data set gathered via a systematic review, and applying an existing mathematical model, we evaluated the impact of several intervention approaches in a high-prevalence setting (Uganda). Our analysis suggests that catch-up vaccination is of limited impact in this setting and that T&T is predicted to have a much greater, sustained impact that performs most consistently across settings ([Fig 7B](#pmed.1003068.g007){ref-type="fig"}). Careful, evidence-based deployment of interventions is essential if sustained and collective progress is to be made towards targets set by the SDGs \[[@pmed.1003068.ref007]\]. Findings of this study highlight the requirement to tailor intervention strategies based on well-informed, high-resolution epidemiological data. This is all the more important for resource-limited settings that are underrepresented in the existing evidence base \[[@pmed.1003068.ref038]\].

![Cartoons to illustrate seroepidemiology of HBV infection in Africa and the differential impact of HBV interventions according to population targeted.\
(A) After exposure to HBV, the risk of developing CHB is highest among young infants, and this risk gradually declines with age until adulthood, when there is low risk of developing CHB. Figure informed by parameters in [S1 Table](#pmed.1003068.s002){ref-type="supplementary-material"}. Artwork supported by figures created with BioRender.com. (B) Populations from Sudan \[[@pmed.1003068.ref039]\], Uganda \[[@pmed.1003068.ref003]\], and Burkina Faso \[[@pmed.1003068.ref040]\] represent approximately the 25th, 50th, and 75th percentiles in the data set collected from our literature review. In adults, assuming that different populations are exposed at the same rate and the risk of CHB is constant (estimated to be 5% in healthy adults as shown in panel A), the incidence of new CHB infection in the population is related to the proportion *S*. Without intervention, 100% of predicted new cases will occur. If 50% of the adult population is vaccinated in a catch-up campaign, CHB will be prevented only among the population *S*. The impact of catch-up vaccination on incidence is therefore related to *S*, with reduced impact in highly exposed populations. In a T&T scenario, with 50% of cases identified and treated, incidence is consistently reduced, regardless of *S*. anti-HBc, antibody to hepatitis B core antigen; *C*, HBsAg prevalence; CHB, chronic hepatitis B; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; *R*, anti-HBc prevalence; *S*, susceptible population; T&T, Test and Treat.](pmed.1003068.g007){#pmed.1003068.g007}

Insights into interventions {#sec020}
---------------------------

The importance of infant vaccination remains paramount and has been well validated in clinical practice, mathematical models, and population epidemiology across diverse settings. In this study, we set out to explore the controversial and less studied approaches of catch-up vaccination and T&T. Although it can seem intuitive to deploy catch-up vaccination for adolescents and adults in high-prevalence settings, only a limited proportion of the population remains susceptible, such that only a minority will benefit from the intervention. Thus, the effectiveness of catch-up is expected to be greater in low-prevalence populations. For this reason, catch-up will frequently not be a prudent use of resources, although in some settings there may be cost benefits in targeting young populations \[[@pmed.1003068.ref041]\], and vaccination may be even more important in regions where hepatitis delta virus (HDV) co-infection is highly prevalent \[[@pmed.1003068.ref042]\].

In contrast, our data suggest that T&T programmes aimed at older children and adults may have great impact, in keeping with the findings of a recent review of vaccination \[[@pmed.1003068.ref034]\] and with economic evaluations \[[@pmed.1003068.ref043]\]. Achieving success through T&T requires multipronged investment including education, laboratory infrastructure, and provision of effective, sustained drug therapy for both HBV infection and HIV/HBV coinfection. Focus on diagnosis is prerequisite \[[@pmed.1003068.ref019], [@pmed.1003068.ref044]\], parallel investment in infrastructure is required to triage cases for treatment (based on including laboratory and radiological criteria), and scrutiny will be required for drug resistance \[[@pmed.1003068.ref045]\].

The epidemiology and dynamics of infection are different in certain high-risk subgroups (healthcare workers, partners and household contacts of infected individuals, sex workers and their clients, men who have sex with men), and continuing to target these individuals with preventive vaccination remains very important. Likewise, we continue to emphasise the importance of routine infant immunization campaigns, which are a cornerstone of elimination strategies \[[@pmed.1003068.ref009]\].

Reasons for regional differences in HBV epidemiology in Africa {#sec021}
--------------------------------------------------------------

As exemplified in this study by the case of Uganda, we find evidence of region-specific differences in exposure, transmission, and chronicity rates. This is consistent with patterns previously described in the literature, with the potential for marked differences in seroepidemiology even between neighbouring villages \[[@pmed.1003068.ref046]\]. A diverse range of factors influence the risk of developing chronicity after acute infection ([Table 1](#pmed.1003068.t001){ref-type="table"}), with age at exposure among the most robustly recognised. Our data suggest that in regions with low CHB prevalence but high exposure (e.g., central Africa), most exposure events may be occurring in adults. In contrast, in Western Africa, the majority of exposure events may be in early life. Careful data collection and review is required to underpin the most effective interventions for specific locations. HBV genotype may also influence local seroepidemiology, given variations in spatial distributions and genotype-specific epidemiological factors such as variations in transmission potential \[[@pmed.1003068.ref047]--[@pmed.1003068.ref049]\]. Likewise, traditional cultural practices that confer exposure to HBV may be common in some regions but not others \[[@pmed.1003068.ref050]\].

10.1371/journal.pmed.1003068.t001

###### Factors that may contribute to regional differences in prevalence of anti-HBc and HBsAg across Africa.

![](pmed.1003068.t001){#pmed.1003068.t001g}

  Factor                                        Rationale for contribution to regional differences in HBV seroepidemiology
  --------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Circulating HBV viral genotype**            Predominant genotype varies by region, with genotype-A common in Southern Africa, genotype-D in the North, and genotype-E in the West \[[@pmed.1003068.ref051]\].
  **Host ethnicity and genetics**               HLA-type and T-cell repertoire have been linked to the ability to control the infection \[[@pmed.1003068.ref052]--[@pmed.1003068.ref054]\].
  **Transmission differences**                  Subtle differences in the transmission patterns (vertical versus horizontal) of the HBV genotypes have been documented.Transmission route is fundamentally linked to age at exposure \[[@pmed.1003068.ref055]\].
  **Age at exposure**                           The probability of developing chronic HBV after exposure is strongly associated with age \[[@pmed.1003068.ref056]\]. Populations with a younger age at exposure are therefore likely to have a higher HBsAg prevalence relative to the anti-HBc prevalence.
  **Coinfection within population**             Risk factors for acquisition of blood-borne viruses overlap between HIV, HBV, and HCV.Egypt and the Nile Delta have some of the highest reported prevalences of HCV globally. Coinfection of HBV and HCV has been linked to spontaneous clearance of HCV although evidence of the impact on HBV remains scarce \[[@pmed.1003068.ref057], [@pmed.1003068.ref058]\].
  **Political instability**                     Central Africa includes several regions disrupted by recent conflict and resulting population migration, with powerful influence on increases in interpersonal violence and sexual assault, reduced access to barrier contraception, inadequate screening of blood products, and reduced access to healthcare, all of which can increase exposure rates in the adult population.
  **Traditional cultural practices**            Exposure to blood-borne viruses is influenced by traditional healing practices, scarification, piercing, tattooing, and nonsterile surgical practice.
  **Uptake of HBV vaccination in the region**   Countries with earlier uptake of the HBV vaccine are likely to have lower anti-HBc and HBsAg prevalence than countries that implemented the vaccine later.Prevalence of vaccine escape mutants may contribute, although data for Africa are scarce \[[@pmed.1003068.ref045]\].

**Abbreviations**: anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HLA, human leukocyte antigen

Relationship between HBV and HIV {#sec022}
--------------------------------

We found no evidence that HIV-positive individuals were more likely to be HBV infected or exposed, in keeping with previous reports \[[@pmed.1003068.ref049]\]. This observation reflects different transmission patterns: HIV is less infectious than HBV when transmitted by blood and is largely sexually transmitted in Africa. In contrast, the risk of developing CHB is high in early life and declines with age. However, robust analysis of the influence of HIV on HBV exposure and acquisition is made difficult by limited data. While we were able to identify a large number of HIV-positive cohorts, only 3 of these had directly comparable HIV-negative cohorts. Among all other published cohorts, which we have assumed to be HIV negative, a background prevalence of HIV infection is likely but not clearly reported.

T&T in the context of HBV guidelines {#sec023}
------------------------------------

Current guidelines for the management of CHB recommend treatment only in certain subgroups, based on risk of liver disease \[[@pmed.1003068.ref013]\]. Thus, deployment of a universal T&T campaign, as modelled in this study (see [Methods](#sec008){ref-type="sec"}), would treat many individuals who do not meet current criteria. The infrastructure and budgets to support this detailed individual assessment are not available in many lower- and middle-income country settings, and there is a call for algorithms to be simplified \[[@pmed.1003068.ref059], [@pmed.1003068.ref060]\]. Relaxing the stringency of assessment for treatment may also have the added benefit of reducing complications from HBV progression, as not all individuals at high risk of cirrhosis or hepatocellular carcinoma (HCC) are detected by current algorithms \[[@pmed.1003068.ref061]\]. Therefore, adopting a universal T&T strategy for HBV would need to be carefully evaluated to consider challenges and risks as well as benefits. Wider deployment of NA therapy involves a need for expanded infrastructure, imposes economic costs, and carries risks of drug side effects and toxicity, as well as raises concerns about nonadherence and the associated potential for increasing the selection of drug resistance \[[@pmed.1003068.ref045]\]. However, these may be offset by the benefits of individual, societal, and economic benefits of reducing the morbidity and mortality of chronic liver disease, as well as the population gains of minimising the risk of transmission.

Caveats and limitations {#sec024}
-----------------------

Our maps highlight important geographical gaps in HBV data ([Fig 3](#pmed.1003068.g003){ref-type="fig"}); furthermore, existing cohorts are often relatively small and biased by the recruitment of specific groups. The published literature does not account for the prevalence of occult HBV, which is rarely detected due to lack of availability and high cost of DNA testing. However, individuals with occult HBV would still generate anti-HBc; thus, while we may be underestimating the prevalence of active infection, these individuals are still included within our exposed population.

We considered individuals to have cleared HBV if they were HBsAg negative and anti-HBc positive. However, a proportion of these individuals may still harbour HBV cccDNA in their liver and are at risk of reactivation, particularly in the context of immunosuppression. T&T strategies (whether using HBsAg and/or HBV DNA) would not identify these individuals, and therefore improved diagnostics and monitoring may be of benefit in high-risk populations.

We did not include data for antibody to HBsAg (anti-HBs) prevalence (immunised population) because a limited number of papers report these together with anti-HBc and HBsAg data. The most common reason for study exclusion from the literature review was no anti-HBc prevalence reported ([Fig 1](#pmed.1003068.g001){ref-type="fig"}). The sensitivity and specificity of serological assays vary \[[@pmed.1003068.ref062]\], which may represent a source of bias or uncertainty in our data set, although our quality appraisal of the literature shows that methods were robustly reported overall. However, making the inclusion criteria more stringent would have limited the number of studies we could include, potentially limiting our overall findings.

Based on the age of adults represented in most of our cohorts and vaccination starting in 1995, we can assume that the majority of participants in the study were unlikely to have been vaccinated in infancy. Future sero-surveys will provide more insights into the impact of routine infant vaccination. We focused on adult populations only, because the age-associated risk of developing chronic HBV is a confounding factor in younger cohorts, making inference about the anti-HBc prevalence challenging across multiple age groups. It would be of interest to determine age-specific prevalence of HBsAg and anti-HBc because age is likely to be an important source of heterogeneity. However, metadata are poorly reported, and we were unable to disaggregate serological data by age.

Our modelled universal T&T intervention does not stratify individuals for therapy but works on the basis of treating anyone who is HBsAg positive. In current clinical practice, guidelines recommend treatment only in the context of high viral load and/or evidence of inflammatory liver disease \[[@pmed.1003068.ref013]\]. However, explicitly stratifying population subgroups for T&T within our framework would have required the inclusion of clinical classes (e.g., liver transaminases, fibroscan scores), which would have added significant uncertainty. Our model framework does not include explicit age-specific or risk-group assumptions regarding force of transmission, and again we argue that little data exist to inform this parameterization. Despite uncertainty in specific variables, the model fixes certain parameters, based on estimates from the literature (e.g., HBeAg is set at 27%, recognising that the confidence intervals around this point estimate are wide and vary between settings \[[@pmed.1003068.ref063], [@pmed.1003068.ref064]\]). Our projections are not intended to be exact quantifications of impact over time but serve as a means of comparing the dynamic and nonlinear outcomes of different strategies.

While we have considered HIV as a precedent for T&T interventions, there are also important differences between HIV and HBV, namely the lack of an HIV vaccine and the shorter average timeframes over which morbidity and mortality evolve in the setting of HIV infection.

Implications for future investigation and practice changes {#sec025}
----------------------------------------------------------

Our data show the potential value of T&T approaches for HBV, building both on experience gained from HIV and on insights into paediatric interventions that we have previously modelled \[[@pmed.1003068.ref009]\]. Further analysis is required to investigate more specifically the populations or contexts in which vaccination strategies or T&T might best be deployed, and the extent to which this intervention is synergistic with other routine interventions (infant vaccination and PMTCT). We advocate significant investment in capacity building for improving HBV diagnosis and treatment, including point-of-care testing, antenatal screening, and provision of TDF. A sustained and systematic commitment to diagnosis and treatment represents a key component of the journey towards HBV elimination.

Supporting information {#sec026}
======================

###### The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses.

(PDF)

###### 

Click here for additional data file.

###### Population data and HBV seroepidemiology for Uganda used to inform a model to determine impact of interventions.

(PDF)

###### 

Click here for additional data file.

###### Details of studies from Africa reporting HBV prevalence data from ≥2 cohorts.

These studies (*n* = 13) were each reported in a single publication but contribute ≥2 data points to our overall analysis. Differences in the cohorts are highlighted in city/location, cohort characteristics, and cohort size. Studies listed in alphabetical order by location.

(PDF)

###### 

Click here for additional data file.

###### Predicted HBsAg prevalence for Northern, Eastern, Southern, Western, and Central Africa, based on a given anti-HBc prevalence.

WLR was performed using cohort size as weight. Predicted HBsAg prevalence by WLR for Northern, Eastern, Southern, Western, and Central Africa at anti-HBc prevalences ranging from 5% to 95%, increasing in increments of 5%. Values are plotted in [S3 Fig](#pmed.1003068.s008){ref-type="supplementary-material"}. WLR, weighted linear regression.

(PDF)

###### 

Click here for additional data file.

###### Results of a systematic literature review to identify evidence or recommendations for use of catch-up HBV vaccination in adolescents and adults in Africa.

(PDF)

###### 

Click here for additional data file.

###### Forest plots of HBsAg and anti-HBc prevalence and proportion of the population remaining susceptible in all studies identified in Africa (1995--2019).

Confidence intervals for the population mean were calculated as $\overset{-}{x} \pm \mspace{360mu} t\prime\frac{S}{\sqrt{n}}$, in which S is the standard deviation, $\overset{-}{x}$ the sample mean, *n* the cohort size, and t' the upper (1 − C)/2 critical value for the t distribution with *n* − 1 degrees of freedom. Panels (a) for anti-HBc, (b) for HBsAg, and (c) for susceptible population. Full metadata online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598).

(PDF)

###### 

Click here for additional data file.

###### Average prevalence of anti-HBc and HBsAg in confirmed HIV-positive cohorts and all other cohorts.

Cohort characteristics were recorded for each study (full metadata online at Figshare: [10.6084/m9.figshare.6154598](https://doi.org/10.6084/m9.figshare.6154598)). All cohorts characterised as HIV positive (*n* = 27) were grouped together and compared with cohorts that were not listed as being HIV positive (*n* = 79). Three cohorts testing sex workers (*n* = 1) and patients in HIV testing clinics (*n* = 2) were excluded from the analysis as not all participants were HIV positive in these cohorts, but HIV-positive participants are likely to be enriched in these cohorts. Weighted averages, accounting for study size, are shown along with 95% confidence intervals. No significant differences were identified for either anti-HBc or HBsAg prevalence (both *p* = 0.06 and *p* = 0.07, respectively).

(PDF)

###### 

Click here for additional data file.

###### Predicted HBsAg prevalence for Northern, Eastern, Southern, Western, and Central regions of Africa with a given total anti-HBc prevalence (reflecting exposure).

WLR was performed using cohort size as weight. Predicted HBsAg prevalence by WLR for Northern, Eastern, Southern, Western, and Central Africa at anti-HBc prevalences ranging from 5% to 95%, increasing in increments of 5%, is presented here. Plotted from values given in [S3 Table](#pmed.1003068.s004){ref-type="supplementary-material"}. WLR, weighted linear regression.

(PDF)

###### 

Click here for additional data file.
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Dear Dr. Matthews,

Thank you very much for submitting your manuscript \"HBV seroepidemiology data for Africa provides insights into transmission and prevention\" (PMEDICINE-D-19-03078) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to four independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Nov 29 2019 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.
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Thomas McBride, PhD

Senior Editor
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Requests from the editors:

1- Please report your SR/MA according to the PRISMA guidelines provided at the EQUATOR site.

<http://www.equator-network.org/reporting-guidelines/prisma/>

Please provide the completed PRISMA checklist. When completing the checklist, please use section and paragraph numbers, rather than page numbers.

2- Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with main concept if possible. \"Effect of\" should be used only if causality can be inferred, i.e., for an RCT. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon).

3- Please structure your abstract using the PLOS Medicine headings (Background, Methods and Findings, Conclusions).

4- Please remove the third sentence of the Abstract ("HBV has been neglected\...") .

5- In the Abstract Methods and Findings, please include information on the modelled population and timeframe for the estimates, and main outcome measures. For the systematic review portion, please provide the dates of search, data sources, number of studies included, types of study designs included, eligibility criteria, and synthesis/appraisal methods.

6- In the Abstract Methods and Findings, please quantify the main results (with 95% CIs and p values).

7- Line 70 and throughout: Unless there is a statistical reason to do so, please report p values down to p= 0.001 and anything smaller as p\<0.001.

8- In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study\'s methodology.

9- At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please

see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

10- Please remove the last sentence of the Introduction ("Our results have immediate potential...").

11- Please include the PRISMA flowchart in the main paper.

12- Please update your literature search to the present time.

13- As noted by reviewer 1, please conduct a meta-analysis.

14- Please evaluate study quality and risk of bias.

15- Though the HBV dynamic model was previously published, please provide more details on the model in the Methods section.

16- Please provide a diagram that shows the model structure, including how the disease natural history is represented, the process and determinants of disease acquisition, and how the putative intervention could affect the system.

17- What were the algorithms used for HBsAg and anti-HBc in the various studies?

18- Does the model take into account non-compliance with drug treatment?

19- Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>

Reference 4, for example, is incomplete.

Comments from the reviewers:

Reviewer \#1: Alex McConnachie, Statistical Review

McNaughton et al look at transmission and prevention of HBV in Africa; this review looks at the statistical aspects of the paper.

The paper involves a systematic review, but no meta-analysis. At least, it is not described as such; the analysis of metadata is done with equal weight given to each study, and groups of studies are compared with standard independent samples tests. This seems wrong - studies should be weighted according to their size, or the precision with which they estimate prevalence.

The phrase \"non-parametric data\" is not correct. It is the test used to analyse the data that is non-parametric, not the data itself. Also, if a non-parametric test is used to compare two groups, then ANOVA for comparing more than two groups is not right; something like a Kruskal-Wallis test would seem appropriate.

The paper then describes the results of adapting a model they have built to explore the impact of adult vaccination, or a Test and Treat approach on HBV control. The model is applied using data obtained from the systematic review specifically from Uganda. The results, shown in Figure 4, appear to include various other strategies, which are not well described in the paper. Also, I do not see the value of projecting the impact of strategies up to 500 years into the future. Even a 50-year horizon is probably beyond most policy-makers considerations.

No attempt appears to have been made to explore the potential impact of different control strategies in different settings. E.g. are there any settings in which a catch-up vaccination strategy would be effective, or in which a T+T strategy less so? There is some speculation about this in the discussion, but it would be better to use the model to investigate what the optimal strategies might be in different settings.

Reviewer \#3: This manuscript describes a systematic review on the prevalence of chronic HBV and modelled estimates of the impact of catch up vaccination or test and treat in Africa. The results suggest heterogenous prevalence of chronic HBV with regional variation. Catch-up vaccination has predictably little impact on chronic HBV prevalence. Test & Treat appears to be an effective method for reducing the prevalence of chronic infection albeit that the impact will take some time to achieve SDG goals.

The wording of the abstract is a little confusing - \"relationship between the prevalence of HBsAg and anti-HBc (p\<0.0001)\" All patients who are HBsAg positive are also anti-HBc positive. It would help if the authors made it clearer that they are talking about prevalence of chronic infection and previous acute infection (exposure)

The term \'infection\' is insufficiently precise. It is important to distinguish acute HBV infection from chronic HBV infection as the risk of cirrhosis and hepatocellular carcinoma are only associated with the latter

Whilst the authors are correct in asserting that catch-up vaccination in adolescents is still being proposed as a public health strategy, in reality this is now rarely advocated. It is well understood that 1. Exposure to the infection takes place earlier in life and 2. Exposure as an adolescent rarely results in chronic infection and is therefore a much less important public health issue. The only situation where catch up vaccination is potentially beneficial is in regions where HDV co-infection is prevalent and spread through sexual transmission

The HBeAg positivity rate amongst those who are HBsAg positive is high (Suppl Table 1) . The rate will vary according to age and is most relevant in pregnant women

Rate of HBeAg clearance uses an estimate from Taiwan rather than data from West Africa - see Shimakawa et al

The paper does not seem to take into account current indications for treatment. If advocating treatment for all patients with chronic infection irrespective of disease phase, level of viraemia etc then this needs discussing in more detail.

Whilst the discussion encompasses consideration of exposure and chronic infection rate variation between African regions it missed the wide variation in prevalence and exposure at a much more granular level - see Whittle JID 1990

I am not comfortable with postulating a role for insect vectors in HBV. This has been examined extensively and is not supported by evidence.

Reviewer \#4: Dear authors,

This is a well-written, excellent, comprehensive and creative article. The authors start with and support the hypothesis that testing and treating hepatitis B may be a viable public health option. The comprehensive literature review of hepatitis B serology and the modelling and compilation of data are clear and well-presented. My comments concern the paper itself.

There are three points that could be better introduced and discussed in the conclusions and recommendations, so that the appropriate focus is brought to the findings. An alternate presentation of data should be considered.

Firstly, the authors state at the outset that there are no recommendations for wide-scale catch-up immunization of adults. Yet the scenario of a single one-off all ages catch-up vaccination campaign is one of the interventions modelled and studied in this paper. The authors then conclude that \'Although it can seem intuitive to deploy catch-up vaccination for adults in high prevalence settings\... only a minority will benefit from the intervention\'. Therefore they appear to advocate a blanket dismissal of \'catch-up\' vaccination which they state is not actually the subject of any recommendation. However the authors have not analyzed targeted vaccination strategies such as for example catch-up vaccination in low EPI coverage settings for young children to reduce childhood horizontal transmission, or assessed alternate booster/catch-up approaches in school-aged children prior to sexual début. So the emphasis on a non-recommended strategy risks detracting from consideration of possibly more useful vaccination and other alternatives. It would be far preferable for example to have the abstract, intro and discussion focus on the impact of vaccination at birth and/or after school entry as these are also modelled and far more relevant from a public health programmes perspective.

The presentation of the models out to 500 years is nice but fanciful, and detracts from closer assessment of alternate strategies, and possible combinations of strategies, over the next ten to 50 years.

My recommendation is to refocus the abstract, introduction and discussion on the range of possible public health interventions that should be considered, not on the one for which they found no recommendations.

The authors should consider also presenting findings to at most 50 or 100 years (or event 200, the relevance of which is also highly questionable) so that readers can really focus on the immediate public health implications of the paper. Highlighting the 2030 goal would add immediacy to the findings. I also recommend removing the data points for the one-off all ages vaccination campaign, as it also detracts from the far more relevant findings. Mentioning those results briefly in the text would be sufficient.

Secondly, the primary thesis of the paper concerns treatment of hepatitis B, yet there is no mention of treatment options upon which the paper relies. Please include a paragraph outlining the treatment options currently being used and some parameters considered (e.g. assumptions about what constitutes successful treatment or assumed success rates, mention of complications attributable to treatment). This does not have to be detailed, but sufficient to orient the reader to the public health intervention being proposed and argued for in this paper.

Thirdly, the practical, logistical and economic feasibility of the T&T intervention is likely at this time to be quite low in the African continent and countries included in the study. The authors draw an analogy with HIV T&T, but there is no HIV vaccine, and those infected remain infectious and face morbidity and mortality much more quickly than chronic HPV carriers do, so it may be an inadequate comparison. The cost is likely to be prohibitive and the systems not in place. Perhaps cervical cancer screening would be a reasonable analogy. In order to orient the reader and provide more targeted recommendations, it would be helpful to provide any examples of where the T&T approach is being piloted for HBV and reference practical considerations.

From a public health programming perspective and the 2030 targets, the most relevant question would be what would be the success of a primary prevention strategy combining 1.PMTCT 2.Routine neonatal HB vaccination and 3.School-based booster/catch-up HB vaccination. Then the question could be asked what is the marginal added value of a T&T intervention at scale. If this paper cannot address such questions now, then it would be helpful to set up the discussion to indicate what are the appropriate questions for public health programmes in Africa, so that subsequent research can pursue them.

Thanks very much for giving me the opportunity to review your excellent paper and I look forward to your further work.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

###### 

Submitted filename: PMEDICINE D -19-03078 Manuscript review (1) (1).docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003068.r002

Author response to Decision Letter 0

2 Dec 2019

###### 

Submitted filename: 191128 T4P response to reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003068.r003

Decision Letter 1

Turner

Richard

Senior Editor

© 2020 Richard Turner

2020

Richard Turner

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

30 Jan 2020

Dear Dr. Matthews,

Thank you very much for re-submitting your manuscript \"Hepatitis B virus seroepidemiology data for Africa: a systematic review and meta-analysis to inform analysis of optimal local intervention strategies\" (PMEDICINE-D-19-03078R1) for consideration at PLOS Medicine.

I have discussed the paper with editorial colleagues and our academic editor, and it was also seen again by the reviewers. I am pleased to tell you that, provided the remaining editorial and production issues are dealt with, we expect to be able to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We hope to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

Please let me know if you have any questions. Otherwise, we look forward to receiving the revised manuscript shortly.

Sincerely,

Richard Turner PhD, for Thomas McBride, PhD

Senior Editor, PLOS Medicine

<rturner@plos.org>

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Please confirm that all other authors have agreed to the inclusion of a new author (UO).

We ask you to amend the title so that it better matches journal style, and suggest \"Analysis of hepatitis B virus seroepidemiology data for Africa and modelling of intervention strategies: a systematic review and meta-analysis\".

In your abstract, around line 71, we suggest adding a sentence, say, to quote aggregate data from the studies found (e.g. those noted at lines 286-287).

We also suggest adding some quantitative details of the \"region specific differences\".

In the abstract and main text, you quote an estimate of \"33%\" for reduction of HBV incidence at 20 years with test and treat programmes, for example. We notice a shaded area in Fig 6E, for example, and wonder whether this refers to a credibility interval, say (we may have missed an explanation in the text)? We ask you to add indications of uncertainty to this and other estimates in your paper, if available.

At line 115, please substitute \"existing\" for \"(previously published)\". Also, please soften the wording here to reflect that modelling is involved, e.g., substituting \"\... is predicted to have a substantial impact\" for \"has\".

Early in the methods section, please state whether the study had a protocol or prespecified analysis plan, and if so attach the relevant document(s) as a supplementary file. Please highlight analyses that were not prespecified.

Please restructure the early part of the discussion section of your main text so that the first paragraph provides a summary of the study\'s findings.

At line 493, please make that \"report data \... these\" (rather than \"this\").

Please make that \"potential value\" at line 533.

Throughout the text, please format reference call-outs as follows: \"\... 2030 targets \[9,10\].\".

Please abbreviate journal names consistently through the reference list.

For reference 1, please correct the group author name and add full access details.

We suggest removing reference 29, and including the access details at the start of your \"Results\" section.

For reference 31, \"S Afr Med J\" will suffice as the journal name.

Please update reference 55.

You mention a completed PRISMA checklist, but we did not find this among the submitted files. Please include this as a separate supplementary file with your revision; and ensure that individual items in the checklist are referred to by section (e.g., \"Methods\") and paragraph number rather than by page or line numbers, as the latter generally change upon publication. Please refer to the checklist in the main text (methods section).

Comments from Reviewers:

\*\*\* Reviewer \#1:

Alex McConnachie, Statistical Review

I thank the authors for their responses to my original points. These are satisfactory, and I have no further comments to make.

One very minor thing I missed first time around. Line 335 includes \"p\>0.05\" - it is usually preferable to report actual p-values.

\*\*\* Reviewer \#2:

has addressed all comments

\*\*\* Reviewer \#3:

I am happy with the authors responses and the revised version of the manuscript. I would make one minor recommendation - It is not entirely true to say that Test & Treat has not been evaluated, as suggested in the abstract. The strategy has been piloted in The Gambia as detailed in references 19 & 44

\*\*\* Reviewer \#4:

In this revised manuscript, the authors have met most of the recommendations of the previous review, including my own, resulting in clearer and more relevant presentation and more nuanced discussion and reommendations.

In referring to outcome of models, it would be preferable to use terms such as \'our models suggest that\...\' rather than \'we have demonstrated that\', and \'would\' or \'could\' rather than definitive statements such as \'was\' or \'will\', including in the plain language summary.

\*\*\*

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003068.r004
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13 Mar 2020

Dear Prof Matthews,

On behalf of my colleagues and the academic editor, Dr. Mirjam Kretzschmar, I am delighted to inform you that your manuscript entitled \"Hepatitis B virus seroepidemiology data for Africa: modelling intervention strategies based on a systematic review and meta-analysis\" (PMEDICINE-D-19-03078R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Richard Turner, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
